Abstract
The HIV pandemic has been associated with a rise in the prevalence of primary and recurrent cryptococcosis. Evidence-based treatment algorithms exist for the use of antifungal drugs and maintaining normal intracranial pressure in HIV-infected hosts with cryptococcal meningitis. Further investigation is needed for the treatment of cases with refractory infections and cryptococcosis-related immune reconstitution syndrome, along with the optimal use of adjuvant therapies. Primary and secondary prevention strategies remain at the crux of global control strategies for cryptococcal disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
